Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B7 | P56937 | 1/20 | 0.60 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656757 | 1.00 | HSD17B7 (0.60) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL7527383 | 1.00 | HSD17B7 (0.60) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL7527375 | 1.00 | HSD17B7 (0.60) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL14561091 | 0.84 | SRD5A1 (0.56) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL7524799 | 0.84 | HSD17B7 (0.57) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL5408042 | 0.84 | SRD5A1 (0.56) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL5427981 | 0.84 | SRD5A1 (0.56) | SRD5A1SRD5A2 | |
| SCHEMBL7524800 | 0.84 | HSD17B7 (0.57) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL5408037 | 0.84 | SRD5A1 (0.56) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL10273977 | 0.84 | CYP19A1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-0705272-B1 | NOVEL PROCESS FOR PREPARING 17 BETA-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | RICHTER GEDEON VEGYESZET (HU) | 2002-03-27 | — | — | EP | disclosed |
| EP-0705272-A1 | NOVEL PROCESS FOR PREPARING 17 BETA-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000531-A1 | NOVEL PROCESS FOR PREPARING 17β-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | CYP4A11, HSD17B11, CYP21A2 | HSD17B7 17/4885SRD5A1 38/4885SRD5A2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.